Biomerica Inc 's Cash & cash equivalent grew by 108.94 % in the Q1 2026 sequentially, faster than Current Liabilities, this led to improvement in Biomerica Inc 's Quick Ratio to 0.96, Quick Ratio remained below Biomerica Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Quick Ratio than Biomerica Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 1961 to 2157.

Explain Quick Ratio?
How much Cash & cash equivalents BMRA�s has?
What are BMRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BMRA/financial-strength

https://api.csimarket.com/api/v1/companies/BMRA/fundamentals

https://api.csimarket.com/api/v1/companies/BMRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BMRA Quick Ratio	(Aug 31 2026) Q1	(May 31 2026) Q4	(Feb 28 2026) Q3	(Nov 30 2025) Q2	(Aug 31 2025) Q1
Y / Y Current Liabilities Change	67.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-10.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.96	Subscribe	Subscribe	Subscribe	Subscribe
BMRA's Total Ranking	# 2157	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	14.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	108.94 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 10
Healthcare Sector	# 633
Overall Market	# 2012

Quick Ratio Statistics
High	Average	Low
5.85	2.19	0.27
(May 31 2020)		(May 31 2016)

Financial Statements
Biomerica Inc 's Current Liabilities	$ 3 Millions	Visit BMRA's Balance sheet
Biomerica Inc 's Cash & cash equivalent	$ 3 Millions	Visit BMRA's Balance sheet
Source of BMRA's Sales		Visit BMRA's Sales by Geography

Cumulative Biomerica Inc 's Quick Ratio

BMRA's Quick Ratio for the trailling 12 Months

BMRA Quick Ratio	(Aug 31 2026) 12 Months	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	21.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-27.22 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.93	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1030	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	15.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-3.88 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BMRA Financial Strength Comparisons >> Go to Compare BMRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q1 2026 to $2.84 millions, cumulative Quick Ratio decreased to 0.93 below the Biomerica Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Biomerica Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending fourth quarter 2026 at 3943.

Explain Quick Ratio?
How much Cash & cash equivalents BMRA�s has?
What are BMRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 897
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.83	2.5	0.62
(Feb 28 2021)		(Nov 30 2019)

Companies with similar Quick Ratio in the quarter ending Aug 31 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Aug 31 2026 MRQ Cash & cash equivalent	Aug 31 2026 MRQ Current Liabilities
Lantheus Holdings Inc	1.98	$ 683.610 Millions	$ 345.967 Millions
Alpha Teknova Inc	1.86	$ 16.560 Millions	$ 8.926 Millions
Biomerica Inc	0.96	$ 2.733 Millions	$ 2.837 Millions
Myriad Genetics Inc	0.78	$ 107.100 Millions	$ 137.600 Millions

Date modified: 2026-10-16T04:51:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.